JP2016525562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525562A5 JP2016525562A5 JP2016530547A JP2016530547A JP2016525562A5 JP 2016525562 A5 JP2016525562 A5 JP 2016525562A5 JP 2016530547 A JP2016530547 A JP 2016530547A JP 2016530547 A JP2016530547 A JP 2016530547A JP 2016525562 A5 JP2016525562 A5 JP 2016525562A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- ethyl
- hydrogen
- methyl
- occurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 104
- 229910052739 hydrogen Inorganic materials 0.000 claims description 102
- 239000001257 hydrogen Substances 0.000 claims description 102
- 150000002431 hydrogen Chemical class 0.000 claims description 76
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- -1 R 4 is not 6-chloro Chemical group 0.000 claims description 14
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 claims description 12
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 201000008827 tuberculosis Diseases 0.000 claims description 5
- JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical group OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000000034 method Methods 0.000 description 4
- 0 C*C(CNC(c1c(*)nc2[n]1cccc2)=O)=C* Chemical compound C*C(CNC(c1c(*)nc2[n]1cccc2)=O)=C* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861750P | 2013-08-02 | 2013-08-02 | |
| US61/861,750 | 2013-08-02 | ||
| PCT/EP2014/066614 WO2015014993A2 (en) | 2013-08-02 | 2014-08-01 | Anti-infective compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018119810A Division JP6757768B2 (ja) | 2013-08-02 | 2018-06-25 | 抗感染症化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525562A JP2016525562A (ja) | 2016-08-25 |
| JP2016525562A5 true JP2016525562A5 (enExample) | 2017-03-23 |
Family
ID=51260879
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530547A Withdrawn JP2016525562A (ja) | 2013-08-02 | 2014-08-01 | 抗感染症化合物 |
| JP2018119810A Active JP6757768B2 (ja) | 2013-08-02 | 2018-06-25 | 抗感染症化合物 |
| JP2019077088A Pending JP2019131606A (ja) | 2013-08-02 | 2019-04-15 | 抗感染症化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018119810A Active JP6757768B2 (ja) | 2013-08-02 | 2018-06-25 | 抗感染症化合物 |
| JP2019077088A Pending JP2019131606A (ja) | 2013-08-02 | 2019-04-15 | 抗感染症化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160185774A1 (enExample) |
| EP (1) | EP3027615B1 (enExample) |
| JP (3) | JP2016525562A (enExample) |
| KR (1) | KR102292293B1 (enExample) |
| CN (2) | CN105745208A (enExample) |
| DK (1) | DK3027615T3 (enExample) |
| ES (1) | ES2883565T3 (enExample) |
| HU (1) | HUE056198T2 (enExample) |
| PH (1) | PH12016500207A1 (enExample) |
| RU (1) | RU2734760C2 (enExample) |
| SG (1) | SG11201600686QA (enExample) |
| WO (1) | WO2015014993A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3316969T2 (ro) * | 2015-07-02 | 2022-07-31 | Janssen Sciences Ireland Unlimited Co | Compuși antibacterieni |
| PE20181352A1 (es) * | 2015-09-17 | 2018-08-22 | Marvin J Miller | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias |
| EP3472152A1 (en) * | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacte rials |
| MA45377A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques en tant qu'agents antibacteriens |
| MA47676A (fr) | 2017-03-01 | 2021-06-02 | Janssen Sciences Ireland Unlimited Co | Polythérapie |
| CN111246848A (zh) | 2017-10-05 | 2020-06-05 | 快尔生物技术公司 | 与抗结核药物组合的环稠和的噻唑并2-吡啶酮 |
| CN108101828B (zh) * | 2018-01-15 | 2021-05-04 | 西华师范大学 | 3-吲哚基甲酰胺类化合物及其制备方法 |
| CN108159049B (zh) * | 2018-02-01 | 2021-01-05 | 中国科学院广州生物医药与健康研究院 | 一种吡啶类化合物的新用途 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| US20220226299A1 (en) * | 2019-03-29 | 2022-07-21 | Nippon Chemiphar Co., Ltd. | Use of t-type calcium channel blocker for treating pruritus |
| TWI861208B (zh) * | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| CN114423758B (zh) * | 2019-09-13 | 2025-05-27 | 爱尔兰詹森科学公司 | 抗细菌化合物 |
| KR20220071199A (ko) * | 2019-09-30 | 2022-05-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4-퀴놀리논 항균 화합물 |
| CA3151712A1 (en) * | 2019-09-30 | 2021-04-08 | Jerome Emile Georges Guillemont | Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis |
| IL328855A (en) | 2019-12-20 | 2026-08-01 | Qurient Co Ltd | Q203 Pharmaceutical Oral Dosage Form |
| KR102381397B1 (ko) * | 2020-07-10 | 2022-03-30 | 경희대학교 산학협력단 | 신규 나프토퀴논 유도체 화합물 및 이를 포함하는 항균용 조성물 |
| WO2022194803A1 (en) | 2021-03-16 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3211592A1 (en) | 2021-03-17 | 2022-09-22 | Jerome Emile Georges Guillemont | Antibacterial compounds |
| MX2023010941A (es) | 2021-03-17 | 2023-11-28 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| CA3234515A1 (en) | 2021-10-28 | 2023-05-04 | Jose Manuel Bartolome-Nebreda | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| JP2025530847A (ja) * | 2022-09-16 | 2025-09-17 | 北京華益健康薬物研究中心 | Ｍｅｔｔｌ３阻害剤化合物、その医薬組成物及び用途 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| JP2026525955A (ja) | 2023-07-18 | 2026-08-04 | ヤンセン ファーマシューティカ エヌ．ベー． | ベダキリン、プレトマニド又はデラマニド、及びシトクロムｂｃ１阻害剤を含む、少なくとも三種の抗生物質の組み合わせ製品、並びにマイコバクテリア感染症の治療におけるそれらの使用 |
| CN117946118A (zh) * | 2024-01-15 | 2024-04-30 | 珃诺生物医药科技(杭州)有限公司 | 一种靶向降解erk5蛋白的化合物及其制备方法 |
| CN119118959A (zh) * | 2024-09-06 | 2024-12-13 | 镇江市高等专科学校 | 4-[4-(氨基甲基)苯基]哌嗪-1-羧酸叔丁酯的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2906250B1 (fr) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
| CA2672960A1 (en) * | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| WO2009140101A2 (en) * | 2008-05-12 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Imidazopyridine compounds useful as mmp-13 inhibitors |
| IN2012DN04917A (enExample) * | 2009-11-05 | 2015-09-25 | Univ Notre Dame Du Lac | |
| RU2576662C2 (ru) * | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
| WO2012143796A2 (en) * | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| CN103324035B (zh) * | 2013-06-20 | 2015-07-01 | 深圳市华星光电技术有限公司 | 掩膜板和阵列基板的制作方法 |
-
2014
- 2014-08-01 WO PCT/EP2014/066614 patent/WO2015014993A2/en not_active Ceased
- 2014-08-01 RU RU2016107378A patent/RU2734760C2/ru active
- 2014-08-01 JP JP2016530547A patent/JP2016525562A/ja not_active Withdrawn
- 2014-08-01 CN CN201480054331.1A patent/CN105745208A/zh active Pending
- 2014-08-01 CN CN201811384685.9A patent/CN109575018A/zh active Pending
- 2014-08-01 EP EP14745158.7A patent/EP3027615B1/en active Active
- 2014-08-01 HU HUE14745158A patent/HUE056198T2/hu unknown
- 2014-08-01 DK DK14745158.7T patent/DK3027615T3/da active
- 2014-08-01 SG SG11201600686QA patent/SG11201600686QA/en unknown
- 2014-08-01 ES ES14745158T patent/ES2883565T3/es active Active
- 2014-08-01 US US14/909,663 patent/US20160185774A1/en not_active Abandoned
- 2014-08-01 KR KR1020167005457A patent/KR102292293B1/ko active Active
-
2016
- 2016-01-29 PH PH12016500207A patent/PH12016500207A1/en unknown
-
2018
- 2018-06-25 JP JP2018119810A patent/JP6757768B2/ja active Active
-
2019
- 2019-04-15 JP JP2019077088A patent/JP2019131606A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016107378A (ru) | Противоинфекционные соединения | |
| JP2018158941A5 (enExample) | ||
| FI94523C (fi) | Kinoliinifungisideja | |
| JP2020521740A5 (enExample) | ||
| JP2015504067A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2018532690A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| JP2012522847A5 (enExample) | ||
| JP2014525420A5 (enExample) | ||
| Monastyrskyi et al. | 4 (1H)-pyridone and 4 (1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities | |
| Le Manach et al. | A novel pyrazolopyridine with in vivo activity in Plasmodium berghei-and Plasmodium falciparum-infected mouse models from structure–activity relationship studies around the core of recently identified antimalarial imidazopyridazines | |
| JP2016505637A5 (enExample) | ||
| Reece et al. | Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections | |
| JOP20240120A1 (ar) | مشتقات 4-فينيل-2-(1h-3،2،1-تريازول-4-يل) بيبيريدين-4-أول كمثبطات لـ apol1 وطرق استخدامها | |
| JP2019508496A5 (enExample) | ||
| US20090306020A1 (en) | Combination therapy comprising diaryl ureas for treating diseases | |
| RU2003103780A (ru) | Соединения фенилпиридазина и содержащие их лекарственные средства | |
| JP2007522159A5 (enExample) | ||
| CN114072404A (zh) | Ret选择性抑制剂及其制备方法和用途 | |
| RU2017118369A (ru) | Соединения для применения в дегельминтизации | |
| JP2019525948A5 (enExample) | ||
| JP2015521156A5 (enExample) |